deferiprone has been researched along with Bone Marrow Failure in 1 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Excerpt | Relevance | Reference |
---|---|---|
"Weekly monitoring of absolute neutrophil count (ANC) under deferiprone therapy in thalassemia patients is recommended to avoid agranulocytosis adverse event." | 7.83 | Frequency of neutropenia among Turkish and Syrian pediatric thalassemia patients under deferiprone monotherapy. ( Belen, BF; Özsevik, SN; Polat, M; Soylu, E, 2016) |
"Weekly monitoring of absolute neutrophil count (ANC) under deferiprone therapy in thalassemia patients is recommended to avoid agranulocytosis adverse event." | 3.83 | Frequency of neutropenia among Turkish and Syrian pediatric thalassemia patients under deferiprone monotherapy. ( Belen, BF; Özsevik, SN; Polat, M; Soylu, E, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Belen, BF | 1 |
Polat, M | 1 |
Özsevik, SN | 1 |
Soylu, E | 1 |
1 other study available for deferiprone and Bone Marrow Failure
Article | Year |
---|---|
Frequency of neutropenia among Turkish and Syrian pediatric thalassemia patients under deferiprone monotherapy.
Topics: Adolescent; Anemia, Aplastic; Anemia, Hemolytic; Blood Transfusion; Bone Marrow Diseases; Bone Marro | 2016 |